I believe there are two primary reasons here;
1. anyone testing a particular product across multiple indications and receiving a 'stop for futility' recommendation needs to make a judgement call on how to proceed. Appropriate step is to stop, evaluate any cross-impact, and proceed with permanent shut down of Chemo or continuing all other trials if issues seen are not related to the other trials planned or in motion. It is more responsible to stop, then proceed, showing proper due diligence was carried out.
2. Class-wise, chemo use is going to be reduced and consistently move from 1st line to 2nd and then 3rd over the next 6-24 months, depending on indication and geography. Deciding where to proceed and what to stop will be driven by that assessment.
Breast cancer is going to include some form of Chemo for a while to come, and possibly an I/O-Chemo or I/O-I/O-Chemo as 1st line treatment. For specific types of BC, Chemo seems, so far, to produce better response than anything else. If they completely cancel BC and Bavi/Chemo - I hope we get to hear reasoning at a scientific/business opportunity level. If they don't cancel and proceed as is, or modify and proceed, it is a strong sign that there is value in proceeding with that combination.
Hopefully this opinion is helpful.
Best,
MH
Market Data 
Markets 
AI
